US stock futures dip as Nvidia earnings spark little cheer
James William Rogers (NYSE:ROG), the Chief Financial Officer of Tempus AI , Inc. (NASDAQ:TEM), recently sold 8,712 shares of the company’s Class A common stock. The shares were sold at a weighted average price of $67.57, totaling approximately $588,669. This transaction was part of a mandated "sell to cover" arrangement to meet statutory tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Rogers holds 221,100 shares of Tempus AI. According to InvestingPro analysis, the stock is currently trading above its Fair Value, with technical indicators suggesting overbought conditions. InvestingPro subscribers have access to 10 additional key insights about Tempus AI’s financial health and market position.
In other recent news, Tempus AI Inc. recently saw a boost in its stock rating to Buy, with a price target increase to $74 by TD Cowen. This upgrade followed the acquisition of Ambry Genetics, a move believed by TD Cowen to position Tempus AI for a broader product portfolio and new market entries. The acquisition, which added a profitable germline testing laboratory with over $300 million in revenue to Tempus AI’s assets, is predicted to facilitate positive free cash flow.
Tempus AI also made headlines with the launch of its personal health concierge app, olivia. This AI-driven app aims to centralize patient health data, providing actionable insights. Olivia allows patients to aggregate their health information from over 1,000 health systems and various health devices into one platform, enhancing patient care.
In a strategic partnership, Genialis recently extended its collaboration with Swiss biopharmaceutical firm Debiopharm, aimed at creating a predictive biomarker for WEE1-targeted therapies. Genialis also announced a multi-year agreement with Tempus AI to validate new RNA-based biomarker algorithms across different cancer types. All these developments highlight Tempus AI’s continued expansion and dedication to advancing precision medicine and patient care through technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.